| Henry Webster Dds Pc | |
|
5465 Lincoln Pond Rd Elizabethtown NY 12932-2026 | |
| (914) 552-0732 | |
| Not Available |
| Full Name | Henry Webster Dds Pc |
|---|---|
| Speciality | Dentist - General Practice |
| Location | 5465 Lincoln Pond Rd, Elizabethtown, New York |
| Authorized Official Name and Position | Henry Webster (PRESIDENT) |
| Authorized Official Contact | 9145520732 |
| Accepts Medicare Insurance | This clinic does not participate in Medicare Program. |
| Mailing Address | Practice Location Address |
|---|---|
| Henry Webster Dds Pc 5465 Lincoln Pond Rd Elizabethtown NY 12932-2026 Ph: () - | Henry Webster Dds Pc 5465 Lincoln Pond Rd Elizabethtown NY 12932-2026 Ph: (914) 552-0732 |
| NPI Number | 1740299700 |
|---|---|
| Provider Enumeration Date | 08/07/2006 |
| Last Update Date | 03/20/2012 |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1740299700 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 1223G0001X | Dentist - General Practice | 040068-1 (New York) | Primary |
News Archive
Patients have been known to hug Lauren Gerson, MD, so overjoyed are they at hearing her words. What does she say to them? Go ahead and eat chocolate.
The Republican presidential nominee took a break from his party's convention in Tampa to address the American Legion in Indianapolis. Meanwhile, one news outlet looks at geographic disparities in services for veterans.
The drug ingenol mebutate (trade name: Picato) has been approved in Germany since November 2012 as a gel for the treatment of certain forms of actinic keratosis in adults. In an early benefit assessment pursuant to the Act on the Reform of the Market for Medicinal Products (AMNOG) the German Institute for Quality and Efficiency in Health Care (IQWiG) examined whether this new drug offers an added benefit over diclofenac/hyaluronic acid gel. Such an added benefit cannot be derived from the dossier, however, as the drug manufacturer did not submit any relevant data: it did not cite any studies that directly compared ingenol mebutate with diclofenac/hyaluronic acid gel, and the method chosen by the manufacturer for an indirect comparison was unsuitable.
Canopus BioPharma, Inc. has announced that the South African Medicines Control Council has granted approval for a Phase II study in 30 cancer patients evaluating the protective effect of CB1400 on the gastrointestional tract from radiation-induced mucositis. This new trial is an important step forward in the development of CB1400 as a novel, preventative, anti-mucositis agent.
› Verified 3 days ago